



DELAWARE HEALTH AND SOCIAL SERVICES  
Division of Medicaid & Medical Assistance



Delaware Pharmacy Services

1-800-999-3371

Fax 302-454-0224

December 2011

Attention Providers:

Delaware currently ranks as one of the top states in the US for the prescribing of amphetamines. In an ongoing effort to combat abuse, diversion, and fraud, Delaware Medicaid & Medical Assistance Program, on the recommendation of the Drug Utilization Review Board, will require adult patients to try and fail a long-acting ADHD medication before approving a shorter-acting one. While individuals respond differently to various medications and a full range of therapeutic options needs to be available for appropriate treatment, *short-acting stimulants are more often misused, abused, or illegally sold or purchased as a drug of abuse.*

For adult patients currently on a short-acting CNS stimulant, longer-acting formulations should be considered for therapy as they often have the advantages of improved compliance, less peak-trough effects that can be seen with twice or thrice daily dosing of immediate-release ADHD medications on dosing, and reduced potential for drug diversion.

Please begin to submit documentation of medical necessity for clients who will need to continue on a short acting CNS stimulant to avoid any interruptions in therapy. Please contact us with any questions or reference the preferred drug list and prior authorization forms for Delaware Medicaid under the following link:

<http://www.dmap.state.de.us/information/pharmacy.html>